Hepatitis C virus

Phase II

This study is currently recruiting participants

To explore the effect on early viral kinetics and viral load and to determine safety, tolerability and anti-viral response for the plasmid DNA vaccine ChronVac-C® administered intramuscularly in combination with electroporation followed by standard of care (SOC) in treatment naïve chronic HCV genotype 1 patients.

A Phase II Open-Label, Randomized, Parallel Group, Safety, Tolerability and Efficacy Study of i.m. Administered ChronVac-C® in Combination With Electroporation Followed by Standard of Care in Chronic Hepatitis C Virus Genotype 1 Infected and Treatment Naïve Subjects.

CVC-202

Chronvac-C®

ChronTech

For more information please go to the study protocol.




HIV, Clade B

Phase I

This study is ongoing, but NOT recruiting participants.

This synthetic DNA vaccine was given to HIV-1 infected subjects whose viral load was undetectable on a HAART regimen, with CD4 lymphocyte count above 400 cells/µL of blood. The study was focused on assessing safety and immune responses generated by PENNVAX®-B + EP in a therapeutic setting.

A Phase I, Open Label Study to Evaluate the Safety, Tolerability, and Immunogenicity of PENNVAX®-B (Gag, Pol, Env) + Electroporation in HIV-1 Infected Adult Participants

HIV-001

PENNVAX®-B

For more information please go to the study protocol.




HIV, Clades A, C, and D

Phase I

This study is currently recruiting participants.

The purpose of this study is to evaluate the safety of and immune response to a primate vaccination with a synthetic DNA vaccine for the HIV subtypes A,C and D followed by a boost with a viral vector based HIV vaccine.

A Study of the Safety and Immunogenicity of PENNVAX®-G DNA (Env & Gag) Administered by Intramuscular Biojector 2000 or CELLECTRA® Intramuscular Electroporation Device Followed by MVA-CMDR (HIV-1 CM235 Env/CM240 Gag/Pol) Boost in Healthy, HIV Uninfected Adults

RV 262

PENNVAX®-G

For more information please go to the study protocol.




Influenza H1N1: 65+ Years

Phase I

This trial is currently recruiting patients

The purpose of this study is to determine whether FVH1, a DNA-based influenza vaccine, will be safe and generally well tolerated in healthy elderly adult volunteers and will result in greater immunogenicity when used to prime the immune response to a dose of a trivalent inactivated seasonal vaccine.

Phase I, Open Label Study of a DNA Vaccine's Ability to Increase the Immune Response to the Trivalent Seasonal Influenza Vaccine in the Elderly

NCTO1587131

FVH1 DNA-based influenza vaccine

Inovio/University of Manitoba, Canada

For more information please go to study protocol.




Influenza H5N1

Phase I

This study has been completed.

This study is evaluating safety, tolerability and immunogenicity of Inovio’s influenza synthetic vaccine for avian influenza (H5N1). The vaccine was administered intradermally followed by electroporation in healthy adults.

Study of VGX-3400X, H5N1 Avian Influenza Virus DNA Plasmid + Electroporation in Healthy Adults

FLU-001

VGX-3400X

For more information please go to the study protocol.




Influenza H5N1 & H1N1: 18-55 Years

Phase I

This study is ongoing, but NOT recruiting participants.

This study is evaluating safety, tolerability and immunogenicity of Inovio’s universal influenza synthetic vaccine covering the subtypes H1 and H5. The vaccine is administered intradermally followed by electroporation in healthy adults.

Phase I, Open Label Study to Evaluate Safety, Tolerability and Immunogenicity of Multiple Combinations of H1 and H5 Influenza Hemagglutinin Plasmids Administered ID Followed by in Vivo Electroporation With CELLECTRA®-3P in Healthy Adults

FLU-101

INO-3510

For more information please go to the study protocol.

Back to Top